High Basal Maximal Standardized Uptake Value (SUVmax) in Follicular Lymphoma Identifies Patients with a Low Risk of Long-Term Relapse
Abstract
:Simple Summary
Abstract
1. Introduction
2. Materials and Methods
2.1. PET/CT Scanning
2.2. Patient Selection
2.3. Statistical Analysis
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Relander, T.; Johnson, N.A.; Farinha, P.; Connors, J.M.; Sehn, L.H.; Gascoyne, R.D. Prognostic Factors in Follicular Lymphoma. J. Clin. Oncol. 2010, 28, 2902–2913. [Google Scholar] [CrossRef] [Green Version]
- Wöhrer, S.; Jaeger, U.; Kletter, K.; Becherer, A.; Hauswirth, A.; Turetschek, K.; Raderer, M.; Hoffmann, M. 18F-fluoro-deoxy-glucose positron emission tomography (18F-FDG-PET) visualizes follicular lymphoma irrespective of grading. Ann. Oncol. 2006, 17, 780–784. [Google Scholar] [CrossRef]
- Cheson, B.D. Role of Functional Imaging in the Management of Lymphoma. J. Clin. Oncol. 2011, 29, 1844–1854. [Google Scholar] [CrossRef] [PubMed]
- Kim, H.J.; Lee, R.; Choi, H.; Paeng, J.C.; Cheon, G.J.; Lee, D.S.; Chung, J.-K.; Kang, K.W. Application of Quantitative Indexes of FDG PET to Treatment Response Evaluation in Indolent Lymphoma. Nucl. Med. Mol. Imaging 2018, 52, 342–349. [Google Scholar] [CrossRef]
- Trotman, J.; Barrington, S.; Belada, D.; Meignan, M.; MacEwan, R.; Owen, C.; Ptáčník, V.; Rosta, A.; Fingerle-Rowson, G.R.; Zhu, J.; et al. Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): Secondary analysis of a randomised, phase 3 trial. Lancet Oncol. 2018, 19, 1530–1542. [Google Scholar] [CrossRef] [Green Version]
- Trotman, J.; Fournier, M.; Lamy, T.; Seymour, J.F.; Sonet, A.; Janikova, A.; Shpilberg, O.; Gyan, E.; Tilly, H.; Estell, J.; et al. Positron Emission Tomography–Computed Tomography (PET-CT) After Induction Therapy Is Highly Predictive of Patient Outcome in Follicular Lymphoma: Analysis of PET-CT in a Subset of PRIMA Trial Participants. J. Clin. Oncol. 2011, 29, 3194–3200. [Google Scholar] [CrossRef] [Green Version]
- Trotman, J.; Luminari, S.; Boussetta, S.; Versari, A.; Dupuis, J.; Tychyj, C.; Marcheselli, L.; Berriolo-Riedinger, A.; Franceschetto, A.; Julian, A.; et al. Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: A pooled analysis of central scan review in three multicentre studies. Lancet Haematol. 2014, 1, e17–e27. [Google Scholar] [CrossRef]
- Luminari, S.; Biasoli, I.; Arcaini, L.; Versari, A.; Rusconi, C.; Merli, F.; Spina, M.; Ferreri, A.J.M.; Zinzani, P.L.; Gallamini, A.; et al. The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: A retrospective study from the FOLL05 randomized trial of the Fondazione Italiana Linfomi. Ann. Oncol. 2013, 24, 2108–2112. [Google Scholar] [CrossRef] [PubMed]
- Barrington, S.F.; Mikhaeel, N.G.; Kostakoglu, L.; Meignan, M.; Hutchings, M.; Müeller, S.P.; Schwartz, L.H.; Zucca, E.; Fisher, R.I.; Trotman, J.; et al. Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J. Clin. Oncol. 2014, 32, 3048–3058. [Google Scholar] [CrossRef] [PubMed]
- Luminari, S.; Biasoli, I.; Versari, A.; Rattotti, S.; Bottelli, C.; Rusconi, C.; Merli, F.; Spina, M.; Ferreri, A.J.M.; Zinzani, P.L.; et al. The prognostic role of post-induction FDG-PET in patients with follicular lymphoma: A subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi (FIL). Ann. Oncol. 2014, 25, 442–447. [Google Scholar] [CrossRef]
- Meignan, M.; Cottereau, A.S.; Versari, A.; Chartier, L.; Dupuis, J.; Boussetta, S.; Grassi, I.; Casasnovas, R.-O.; Haioun, C.; Tilly, H.; et al. Baseline Metabolic Tumor Volume Predicts Outcome in High–Tumor-Burden Follicular Lymphoma: A Pooled Analysis of Three Multicenter Studies. J. Clin. Oncol. 2016, 34, 3618–3626. [Google Scholar] [CrossRef]
- Thie, J.A. Understanding the standardized uptake value, its methods, and implications for usage. J. Nucl. Med. 2004, 45, 1431–1434. [Google Scholar] [PubMed]
- Strati, P.; Ahmed, M.A.A.; Fowler, N.H.; Nastoupil, L.J.; Samaniego, F.; Fayad, L.E.; Hagemeister, F.B.; Romaguera, J.E.; Rodriguez, A.; Wang, M.; et al. Pre-treatment maximum standardized uptake value predicts outcome after frontline therapy in patients with advanced stage follicular lymphoma. Haematologica 2019, 105, 1907–1913. [Google Scholar] [CrossRef] [PubMed]
- Zhou, Y.; Zhao, Z.; Li, J.; Zhang, B.; Sang, S.; Wu, Y.; Deng, S. Prognostic values of baseline, interim and end-of therapy 18F-FDG PET/CT in patients with follicular lymphoma. Cancer Manag. Res. 2019, 11, 6871–6885. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Boellaard, R.; O’Doherty, M.J.; Weber, W.A.; Mottaghy, F.M.; Lonsdale, M.N.; Stroobants, S.G.; Oyen, W.J.; Kotzerke, J.; Hoekstra, O.S.; Pruim, J.; et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: Version 1.0. Eur. J. Nucl. Med. Mol. Imaging 2009, 37, 181–200. [Google Scholar] [CrossRef] [Green Version]
- Chiaravalloti, A.; Danieli, R.; Abbatiello, P.; di Pietro, B.; Travascio, L.; Cantonetti, M.; Guazzaroni, M.; Orlacchio, A.; Simonetti, G.; Schillaci, O. Factors affecting intrapatient liver and mediastinal blood pool ¹⁸F-FDG standardized uptake value changes during ABVD chemotherapy in Hodgkin’s lymphoma. Eur. J. Nucl. Med. Mol. Imaging 2014, 41, 1123–1132. [Google Scholar] [CrossRef]
- Swerdlow, S.H.; Campo, E.; Pileri, S.A.; Harris, N.L.; Stein, H.; Siebert, R.; Advani, R.; Ghielmini, M.; Salles, G.A.; Zelenetz, A.D.; et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016, 127, 2375–2390. [Google Scholar] [CrossRef] [Green Version]
- Dreyling, M.; Ghielmini, M.; Rule, S.; Salles, G.; Vitolo, U.; Ladetto, M. ESMO Guidelines Committee. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2016, 27, v83–v90. [Google Scholar] [CrossRef] [PubMed]
- Klein, U.; Dalla-Favera, R. Germinal centres: Role in B-cell physiology and malignancy. Nat. Rev. Immunol. 2008, 8, 22–33. [Google Scholar] [CrossRef]
- Solal-Céligny, P.; Roy, P.; Colombat, P.; White, J.; Armitage, J.O.; Arranz-Saez, R.; Au, W.Y.; Bellei, M.; Brice, P.; Caballero, D.; et al. Follicular Lymphoma International Prognostic Index. Blood 2004, 104, 1258–1265. [Google Scholar] [CrossRef] [Green Version]
- Federico, M.; Bellei, M.; Marcheselli, L.; Luminari, S.; Lopez-Guillermo, A.; Vitolo, U.; Pro, B.; Pileri, S.; Pulsoni, A.; Soubeyran, P.-L.; et al. Follicular Lymphoma International Prognostic Index 2: A New Prognostic Index for Follicular Lymphoma Developed by the International Follicular Lymphoma Prognostic Factor Project. J. Clin. Oncol. 2009, 27, 4555–4562. [Google Scholar] [CrossRef] [Green Version]
- Brice, P.; Bastion, Y.; Lepage, E.; Brousse, N.; Haioun, C.; Moreau, P.; Straetmans, N.; Tilly, H.; Tabah, I.; Solal-Céligny, P. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: A randomized study from the Groupe d’Etude des Lymphomes Folliculaires. Groupe d’Etude des Lymphomes de l’Adulte. J. Clin. Oncol. 1997, 15, 1110–1117. [Google Scholar] [CrossRef]
- Rummel, M.J.; Kaiser, U.; Balser, C.; Stauch, M.; Brugger, W.; Welslau, M.; Niederle, N.; Losem, C.; Boeck, H.-P.; Weidmann, E.; et al. Study Group Indolent Lymphomas. Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: A multicentre, randomised, open-label, non-inferiority phase 3 trial. Lancet Oncol. 2016, 17, 57–66. [Google Scholar] [CrossRef]
- Cheson, B.D.; Fisher, R.I.; Barrington, S.; Cavalli, F.; Schwartz, L.H.; Zucca, E.; Lister, T.A. Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification. J. Clin. Oncol. 2014, 32, 3059–3067. [Google Scholar] [CrossRef] [PubMed]
- Cottereau, A.S.; Versari, A.; Luminari, S.; Dupuis, J.; Chartier, L.; Casasnovas, R.-O.; Berriolo-Riedinger, A.; Menga, M.; Haioun, C.; Tilly, H.; et al. Prognostic model for high-tumor-burden follicular lymphoma integrating baseline and end-induction PET: A LYSA/FIL study. Blood 2018, 131, 2449–2453. [Google Scholar] [CrossRef]
- Karam, M.; Feustel, P.J.; Vera, C.D.; Nazeer, T. Features of large cell transformation of indolent lymphomas as observed on sequential PET/CT. Nucl. Med. Commun. 2011, 32, 177–185. [Google Scholar] [CrossRef] [PubMed]
- Rossi, C.; Tosolini, M.; Gravelle, P.; Pericart, S.; Kanoun, S.; Evrard, S.; Gilhodes, J.; Franchini, D.-M.; Amara, N.; Syrykh, C.; et al. Baseline SUVmax is related to tumor cell proliferation and patient outcome in follicular lymphoma. Haematologica 2020, 105. [Google Scholar] [CrossRef]
- Ladetto, M.; Lobetti-Bodoni, C.; Mantoan, B.; Ceccarelli, M.; Boccomini, C.; Genuardi, E.; Chiappella, A.; Baldini, L.; Rossi, G.; Pulsoni, A.; et al. Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program. Blood 2013, 122, 3759–3766. [Google Scholar] [CrossRef]
- Delfau-Larue, M.-H.; Van Der Gucht, A.; Dupuis, J.; Jais, J.-P.; Nel, I.; Beldi-Ferchiou, A.; Hamdane, S.; Benmaad, I.; Laboure, G.; Verret, B.; et al. Total metabolic tumor volume, circulating tumor cells, cell-free DNA: Distinct prognostic value in follicular lymphoma. Blood Adv. 2018, 2, 807–816. [Google Scholar] [CrossRef] [PubMed]
All Patients | Group A | Group B | p Value * | |
---|---|---|---|---|
Tot = 94 N° (%) | Tot = 34 N° (%) | Tot = 60 N° (%) | ||
Histological Grading | 0.409 | |||
1–2 | 47 (50) | 21 (44.7) | 26 (55.3) | |
3a | 41 (43.6) | 11 (26.8) | 30 (73.2) | |
Undetermined | 5 (5.3) | 2 (40) | 3 (60) | |
Ann Arbor Stage | 0.01 | |||
I–II | 38 (40.4) | 19 (50) | 19 (50) | |
III–IV | 56 (59.6) | 15 (26.8) | 41 (73.2) | |
Bulky Disease | 0.191 | |||
No | 61 (83.6) | 22 (36.1) | 39 (63.9) | |
Yes | 12 (16.4) | 2 (16.7) | 10 (83.3) | |
Bone Marrow Involvement | 0.869 | |||
Negative | 63 (67.7) | 22 (34.9) | 41 (65.1) | |
Positive | 30 (32.3) | 11 (36.7) | 19 (63.3) | |
Extranodal Disease | 0.204 | |||
No | 56 (60.2) | 17 (30.4) | 39 (69.6) | |
Yes | 37 (39.8) | 16 (43.2) | 21 (56.8) | |
B Symptoms | 0.496 | |||
No | 82 (88.2) | 31 (37.8) | 51 (62.2) | |
Yes | 11 (11.8) | 3 (27.8) | 8 (72.2) | |
N° Nodal Sites | 0.065 | |||
≤3 | 34 (38.6) | 16 (47.1) | 18 (52.9) | |
>3 | 54 (61.4) | 15 (27.8) | 39 (72.2) | |
β2-Microglobulin | 0.252 | |||
≤ULN | 64 (82.1) | 24 (37.5) | 42(62.5) | |
>ULN | 14 (17.9) | 3 (21.4) | 11 (78.6) | |
LDH | 0.367 | |||
≤ULN | 70 (85.4) | 27 (38.6) | 43 (61.4) | |
>ULN | 12 (14.6) | 3 (25) | 9 (75) | |
FLIPI | 0.57 | |||
Low risk | 43 (48.3) | 18 (41.8) | 25 (58.1) | |
Intermediate risk | 28 (31.5) | 10 (35.7) | 18 (64.3) | |
High risk | 18 (20.2) | 5 (27.8) | 13(72.2) | |
FLIPI 2 | 0.36 | |||
Low risk | 56 (66.7) | 20 (35.7) | 36 (64.3) | |
Intermediate risk | 20 (23.8) | 8 (40) | 12 (60) | |
High risk | 8 (9.5) | 1 (12.5) | 7 (87.5) |
PFS at Time of Follow-Up | p Value * | |||
---|---|---|---|---|
All Patients N° (%) | Group A N° (%) | Group B N° (%) | ||
Histological Grading | ||||
1–2 | 37 (78.7) | 14 (66.7) | 23 (88.5) | 0.046 |
3a | 34 (82.9) | 7 (63.6) | 27 (90) | 0.031 |
Undetermined | 5 (100) | 2 (100) | 3 (100) | |
Ann Arbor Stage | ||||
I–II | 31 (81.6) | 14 (73.7) | 17 (89.5) | 0.075 |
III–IV | 46 (82.1) | 9 (60) | 37 (90.2) | 0.014 |
Bulky Disease | ||||
No | 47 (77) | 12 (54.5) | 35 (89.7) | <0.001 |
Yes | 10 (83.3) | 2 (100) | 8 (80) | 0.456 |
Bone Marrow Involvement | ||||
No | 53 (84.1) | 15 (68.2) | 38 (92.7) | 0.003 |
Yes | 23 (76.7) | 7 (63.6) | 16 (84.2) | 0.855 |
Extranodal Disease | ||||
No | 47 (83.9) | 11 (64.7) | 36 (92.3) | 0.001 |
Yes | 29 (78.4) | 11 (68.8) | 18 (85.7) | 0.855 |
B Symptoms | ||||
No | 66 (80.5) | 20 (64.5) | 46 (90.2) | 0.001 |
Yes | 10 (90.9) | 3 (100) | 7 (87.5) | 0.386 |
N° Nodal Sites | ||||
≤3 | 29 (85.3) | 12 (75) | 17 (94.4) | 0.028 |
>3 | 43 (79.6) | 9 (60) | 34 (87.2) | 0.059 |
Β2-Microglobulin | ||||
≤ULN | 52 (81.3) | 16 (66.7) | 36 (90) | 0.015 |
>ULN | 12 (85.7) | 2 (66.7) | 10 (90.9) | 0.307 |
LDH | ||||
≤ULN | 58 (82.9) | 19 (70.4) | 39 (90.7) | 0.026 |
>ULN | 9 (75) | 1 (33.3) | 8 (88.9) | 0.093 |
FLIPI | ||||
Low risk | 35 (81.4) | 12 (66.7) | 23 (92) | 0.012 |
Intermediate risk | 27 (96.4) | 9 (90) | 18 (100) | 0.180 |
High risk | 12 (66.7) | 2 (40) | 10 (76.9) | 0.347 |
FLIPI 2 | ||||
Low risk | 48 (62.5) | 15 (75) | 33 (91.7) | 0.021 |
Intermediate risk | 17 (85) | 5 (62.5) | 12 (100) | 0.137 |
High risk | 5 (62.5) | 0 (0) | 5 (71.4) | 0.327 |
Treatment/Response | All Patients | Group A | Group B | p Value * |
---|---|---|---|---|
DF-Pts/Tot (%) | DF-Pts/Tot (%) | DF-Pts/Tot (%) | ||
I line Therapy | ||||
Radiotherapy | 16/22 (72.7) | 7/12 (58.3) | 9/10 (90) | 0.124 |
R-CHOP | 22/27 (81.5) | 7/9 (77.8) | 15/18 (83.3) | 0.278 |
R-Benda | 30/34 (88.2) | 5/7 (71.4) | 25/27 (92.6) | 0.062 |
Other therapies | 7/11 (66) | 4/7 (57) | 3/4 (75) | 0.480 |
Response after induction | ||||
CR | 65/78 (83.3) | 17/26 (65.4) | 48/52 (90.3) | 0.007 |
PR | 5/8 (62.5) | 2/4 (50) | 3/4 (75) | 0.364 |
Transformation at relapse | ||||
No | 77/91 (84.6) | 23/32 (71.9) | 54/59 (91.5) | 0.008 |
Yes | 0/3 | 0/2 | 0/1 | 0.225 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Assanto, G.M.; Ciotti, G.; Brescini, M.; De Luca, M.L.; Annechini, G.; D’Elia, G.M.; Agrippino, R.; Del Giudice, I.; Martelli, M.; Chiaravalloti, A.; et al. High Basal Maximal Standardized Uptake Value (SUVmax) in Follicular Lymphoma Identifies Patients with a Low Risk of Long-Term Relapse. Cancers 2021, 13, 2876. https://doi.org/10.3390/cancers13122876
Assanto GM, Ciotti G, Brescini M, De Luca ML, Annechini G, D’Elia GM, Agrippino R, Del Giudice I, Martelli M, Chiaravalloti A, et al. High Basal Maximal Standardized Uptake Value (SUVmax) in Follicular Lymphoma Identifies Patients with a Low Risk of Long-Term Relapse. Cancers. 2021; 13(12):2876. https://doi.org/10.3390/cancers13122876
Chicago/Turabian StyleAssanto, Giovanni Manfredi, Giulia Ciotti, Mattia Brescini, Maria Lucia De Luca, Giorgia Annechini, Gianna Maria D’Elia, Roberta Agrippino, Ilaria Del Giudice, Maurizio Martelli, Agostino Chiaravalloti, and et al. 2021. "High Basal Maximal Standardized Uptake Value (SUVmax) in Follicular Lymphoma Identifies Patients with a Low Risk of Long-Term Relapse" Cancers 13, no. 12: 2876. https://doi.org/10.3390/cancers13122876
APA StyleAssanto, G. M., Ciotti, G., Brescini, M., De Luca, M. L., Annechini, G., D’Elia, G. M., Agrippino, R., Del Giudice, I., Martelli, M., Chiaravalloti, A., & Pulsoni, A. (2021). High Basal Maximal Standardized Uptake Value (SUVmax) in Follicular Lymphoma Identifies Patients with a Low Risk of Long-Term Relapse. Cancers, 13(12), 2876. https://doi.org/10.3390/cancers13122876